Test Price
2,800 AED✅ Home Collection Available
MID1 Gene Opitz G/BBB Syndrome Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
The MID1 NGS genetic test provides definitive diagnosis for Opitz G/BBB syndrome with 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing. VIP Mobile Phlebotomy home collection is available daily from 8 AM to 11 PM with temperature-controlled cold-chain transport. Post-test telephonic interpretation is provided by a DHA-licensed Consultant Medical Genetics. Insurance billing verification can be arranged via WhatsApp +971 54 548 8731.
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing
- ✓Premium Logistics: Paid Hospital‑Grade Home Collection via ISO‑Certified Cold‑Chain Phlebotomy (VIP Mobile Service)
- ✓Clinical Guidance: Telephonic Post‑Test Interpretation Support by a DHA‑licensed Consultant Medical Genetics
- ✓Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This Next‑Generation Sequencing test analyses the entire coding region of the MID1 gene to confirm or rule out Opitz G/BBB syndrome, a genetic disorder characterized by midline defects and neurological impairment. The test detects single nucleotide variants, small insertions/deletions, and copy number variations with high precision.
| Feature | Our Test (MID1 NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | 99.9% analytical sensitivity & specificity | ~95% (may miss deep intronic variants) |
| Methodology | NGS with CNV detection & MLPA confirmation | Sanger sequencing of limited exons |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Coverage | Full gene ± flanking intronic regions | Selected exons only |
| Result Interpretation | ACMG guidelines + DHA tele‑guidance | Basic report without clinical support |
Physician Insight & Safety Protocols
"The MID1 NGS test is a robust tool for confirming Opitz G/BBB syndrome, but it must be interpreted alongside clinical evaluation. A positive result enables targeted surveillance and early intervention, while a negative result does not exclude the condition if strong clinical suspicion exists. Genetic counselling is essential before and after testing."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Note
⚠ Medication Warning: Do not discontinue any prescribed medication before or after this test without consulting your doctor. This is a genetic screening test and does not replace acute medical management.
Exclusion Criteria & Safety Red Flags
- Inability to provide informed consent (use legal guardian; minors require parent/guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Active severe bleeding disorder or uncontrolled coagulopathy – discuss alternative sample types (buccal swab) with our lab.
- If the patient experiences acute neurological deterioration (e.g., seizures, loss of consciousness, severe respiratory distress), seek emergency care immediately — genetic testing is not an emergency procedure.
Patient FAQ & Clinical Guidance
1. What does the MID1 genetic test detect and who should consider it?
Snippet: This test identifies pathogenic variants in the MID1 gene causing Opitz G/BBB syndrome, characterized by hypospadias, laryngeal cleft, and hypertelorism. It is recommended for children with suggestive clinical features or a positive family history.
2. How is the test performed and is a blood sample mandatory?
Snippet: We accept whole blood (EDTA), extracted DNA (≥2 µg), or a single dried blood spot on an FTA card. A certified phlebotomist collects the sample during a paid home visit, and DNA extraction follows ISO-accredited protocols.
3. What is the clinical interpretation and next steps after receiving my MID1 result?
Snippet: Results are classified according to ACMG guidelines as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. A DHA-registered Consultant Medical Genetics will call you to explain the findings and recommend follow-up management or genetic counselling.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Our facility holds DHA License No. 1143 and is ISO 9001:2015 certified. The testing methodology is aligned with best practices for genetic diagnostics using NGS with CNV detection and MLPA confirmation.
Data Protection: All patient data is encrypted, stored securely, and processed in compliance with UAE data privacy regulations. No data is shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | MID1 Gene Opitz G/BBB Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA (≥2 µg), or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV detection and MLPA confirmation |
| ICD-10-CM Code | Q87.89, Q87.0, Z13.7 |
| LOINC Code | 82939-0 |
| DHA Facility License & Laboratory Address Invariants | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians